Catalyst
Slingshot members are tracking this event:
Celyad (CYAD) Posts Phase 1 Dose-Escalation Data Evaluating NKG2D CAR-T Cells in Patients with Acute Myeloid Leukemia (AML) or Multiple Myeloma for Presentation at the 58th American Society of Hematology (ASH) Annual Meeting on December 3-6
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CYAD |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 06, 2016
Occurred Source:
http://www.celyad.com/news/celyad-announces-positive-new-data-from-its-car-t-nkr-2-phase-i-trial-at-2016-ash-annual-meeting
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1, Dose-escalation Trial, Nkg2d, Car-t Cells, Acute Myeloid Leukemia, Multiple Myeloma, American Society Of Hematology, Annual Meeting
